Full-Time

Senior Director Field Force Effectiveness

Neuroscience

Confirmed live in the last 24 hours

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

Biotechnology
Healthcare

Compensation Overview

$225k - $281.5kAnnually

+ Discretionary Bonus + Equity Awards

Senior, Expert

Princeton, NJ, USA + 1 more

More locations: San Diego, CA, USA

This position requires in-office work three days per week on average.

Category
Field Sales
Strategic Account Management
Sales & Account Management
Required Skills
Excel/Numbers/Sheets

You match the following Acadia Pharmaceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Requires a Bachelor’s degree in marketing, health care, business administration or related field, or an equivalent combination of relevant education and experience may be considered. MBA a plus
  • A minimum of 12 years of progressively responsible experience within the pharmaceutical or biotech industry with demonstrated proficiency in biopharmaceutical field incentive compensation, field force deployment, targeting, field force performance analytics
  • Requires at least 3 years’ of combined experience working in a commercial analytics, incentive compensation and/or field operations (ex. deployment, targeting etc.) roles supporting field based teams. Requires at least 2 years of people management experience
  • Proven success in leadership position with the ability to establish a clear vision, strategies and initiatives to optimize the effectiveness of field base teams
  • Demonstrated success in optimizing field force effectiveness by leveraging performance metrics and implementing deployment, alignment, and targeting strategies
  • Strong knowledge of incentive compensation plan design and administration
  • Previous direct report management experience with the proven ability to establish clear expectations, motivate, manage performance, and to coach others
  • Proven success building strong working relationships with field leadership and other cross functional partners
  • Ability to think critically and form a methodical analytic approach to solve business problems
  • Knowledgeable in commercial data warehouse concepts, industry physician/patient/payer level data, VeevaCRM platform, and reporting tools (PowerBI and/or similar analytics reporting software)
  • Highly proficient with MS Excel and PowerPoint
  • Well organized with a proven ability to multitask, prioritize, delegate, and manage shifting strategies/tactics/responsibilities in a dynamic, cross-functional teamwork environment
  • Strong interpersonal and cross-functional collaboration skills
  • Excellent verbal and written communication skills with the ability to communicate complex concepts and ideas to leadership and the field teams in a easy to understand and relatable terms
  • Ability to challenge the status quo and drive organizational action
Responsibilities
  • Lead and administer the field deployment, sizing, and territory alignment efforts for the Neuro Science group by partnering with sales, marketing, patient services and account management leadership to ensure that Acadia’s field teams are optimally deployed to achieve commercial objectives
  • Lead and administer the field targeting and POA call planning/optimization process by working with commercial leadership teams to ensure that our field teams are focused on the right customers with the right contact frequency, by leveraging the right promotional to channel with the right discussion topic to ensure our patients have access and receive the best treatment outcomes from our products
  • Help inform the commercialization plan for potential new assets as well as existing commercial brands, particularly as it relates to sales force sizing requirements, call plan, identification of target customers, and overall market opportunity
  • Lead the design and the administer of the field incentive compensation, contest/award functional area for the US Neuro Science field teams by collaborating with internal stakeholder and vendors to ensure that plans are motivating, rewarding, and are align with business objectives
  • Lead the evaluation, development, design and administer IC Plans, contests, and annual awards for Neuro Science field teams, , along with their field management teams
  • Provide leadership around governance, inquires, and approval process for IC plans, contests, and awards
  • Implement strategies and the administrative processes to ensure accurate performance and bonus/contest payout calculations
  • Ensure timely communication and documentation to the field teams around IC/contest/award plans, IC goals, IC performance status reports(scorecards), and the administration processes
  • Collaborate with others on the CIAO team and IT on data governance to ensure the consistent performance metric definitions are being utilized and that the necessary data integrations needed for IC are accurate, efficient, and reliable
  • Lead and administer US Neuro Science field-based performance analysis and reporting capabilities at a national, sub-national and customer level by working with sales, patient services, and national account leadership
  • Monitor and assess execution against key business targets to identify gaps and business opportunities, including the assessment of current business situation utilizing key sales performance dashboards and reports to provide insights and make recommendations to on market/ /customer opportunities and field force effectiveness improvements to ensure objectives are met in advancing patient care
  • Work with sales and patient service management to assist in analyzing performance , facilitating business reviews, and examining the execution and effectiveness of POA and field based initiatives
  • Partnering with Commercial System and Analysis group to ensure reporting platforms and metrics/KPIs are aligned to achieve sales objectives and goals
  • Working closely with patient and distribution team, lead efforts in monitoring and providing key performance insights and recommendations surrounding the patient on-boarding, pull-thru, support service and product distribution experience including identify potential bottlenecks, and opportunities
  • Provide input and support for the POA and Brand planning process and ensuring key outputs and initiatives affecting the field teams are implanted on time
  • Collaborate with CIAO and the IT groups to ensure systems and data infrastructure (data warehouse), along with its governance/process, around alignment, targeting, incentive compensation, Veeva CRM, syndicated 3-party data, and sales force performance reporting capabilities are designed to support the US field force objectives and needs
  • Lead efforts, by partnering with sales training, to improve the business skills of the field management team and field personnel with the goals of; improved territory management, business acumen skills, and overall performance
Desired Qualifications
  • MBA a plus
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, which are then approved by regulatory bodies like the FDA before being sold to patients and healthcare providers. What sets Acadia apart from competitors is its commitment to addressing unmet medical needs in neuroscience, along with its focus on corporate social responsibility, including diversity and inclusion. The goal of Acadia Pharmaceuticals is to improve the quality of life for individuals suffering from challenging neurological diseases through effective treatments.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$813.4M

Headquarters

Dallas, Texas

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's recent Health Canada approval for Daybue boosts its market presence in Canada.
  • The exclusive license agreement with Saniona expands Acadia's drug portfolio with SAN711.
  • Hiring Thomas Andrew Garner as CCO strengthens Acadia's commercial leadership team.

What critics are saying

  • Increased competition in CNS drugs may impact Acadia's market share and growth.
  • Regulatory challenges could delay or prevent new drug approvals, affecting revenue.
  • High drug development costs may strain financial resources if trials are unsuccessful.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on unmet needs in neurological disorders like Parkinson's and Rett syndrome.
  • The company has a strong R&D pipeline with four product candidates in development.
  • Acadia collaborates with partners like Biovail to enhance drug development and commercialization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Company News

Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Yahoo Finance
Aug 15th, 2024
Ryan Reynolds Announces More To Parkinson'S(R) Campaign

Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia